 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that four abstracts related to the Companys work in Dravet syndrome have been selected for presentation at the upcoming American Epilepsy Society AES 2020 Virtual Annual Meeting, taking place December 4 8, 2020. Dravet syndrome is a severe and progressive genetic 